FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
A final analysis of data from the phase III ALINA study confirmed the ALK tyrosine kinase inhibitor alectinib’s superiority to chemotherapy as adjuvant treatment for patients with operable ...
Alecensa achieved a 4-year OS rate of 98.4% in resected ALK-positive early-stage NSCLC, outperforming chemotherapy. The ALINA study showed a 65% reduction in disease recurrence or death risk with ...
Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
Panelists discuss how they prepare patients for ALK inhibitor therapy following a confirmed ALK-positive result. Once ALK positivity is confirmed, providers must prepare patients to begin targeted ...
Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first patient had been dosed in ALKAZAR, which is its global Phase 3 randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback